Skip to primary navigation Skip to main content
0 item $0.00

Dr David Greening

BSc(Hons) | PhD, University of Melbourne

Dr David Greening

Head: Molecular Proteomics

Fellowship supported by Helen Amelia Hains Foundation

 

Download my VCF card

Laboratory Head

+61 3 8532 1111

Dr Greening is Head of Molecular Proteomics and Helen Amelia Hains Fellow at Baker Heart and Diabetes Institute, and group leader at La Trobe Institute for Molecular Science, La Trobe University.

He leads an innovative research program that seeks to identify mechanisms of cell communication through secreted factors and extracellular vesicles (EVs), and their capacity to regulate various pleiotropic biological processes of target cells through horizontal transfer of protein, DNA and RNA species between cells. This capability highlights their potential as novel targets for disease intervention, drug development and therapeutic applications. Not surprisingly, EVs (exosomes and microparticles among other types of EVs) have emerged as biomarkers for disease diagnosis and prognosis and are being constructed as targeted therapeutics.

Dr Greening undertook his PhD at The University of Melbourne and Ludwig Institute for Cancer Research, with further post-doctoral fellowship training at the Ludwig Institute for Cancer Research, Walter and Eliza Hall Institute of Medical Research, focused on proteomics, biomarker discovery and protein chemistry, and Institute for Systems Biology (USA) and La Trobe University on cell signalling biology, large-data bioinformatics, protein networks, and systems biology.

Dr Greening has extensive experience in high resolution quantitative mass spectrometry-based proteomics, where he has developed and applied secretome and blood-based proteomics in discovery and preclinical analyses (biomarker discovery). The focus of the laboratory is a multi-disciplinary approach to understand the molecular function of EVs incorporating proteomics, cell biology, molecular biology, nanobiotechnology, functional assays, cell and animal models, with the goal of understanding mechanisms of cell signalling and function, identifying deliverable therapeutic targets and engineering nanoparticles for next generation cell-free therapies in in normal physiology and pathologies; including cancer and cardiometabolic disease.

His research has attracted national funding totalling $5.6M, including NHMRC and internal university and biotechnology partnership funding. He has published 81 papers in leading interdisciplinary journals including Nature Reviews Clinical Oncology, Molecular Psychiatry, Molecular Cellular Proteomics, Proteomics, Journal of Clinical Investigation and Biology of Reproduction. His papers are significantly cited more than expected in Medicine/Physiology (Greening=13.3 vs world=1.0 category normalised citation impact, SciVal). Dr Greening’s research has been translated into several commercial avenues internationally, where he has several provision patents as a co-inventor.

Previously, he has edited two seminal textbooks in the field, Serum/Plasma Proteomics, >180,000 accesses). Dr Greening is President Aust/NZ Soc. EVs, editorial boards of Proteomics and Bioengineering, and grant reviewer (NHMRC, ARC, and in France, US, UK, and Netherlands). Dr Greening is a recipient of several prestigious awards, including ROYAN International Research Award on Reproductive Biomedicine, International Protein Society Hans Neurath Outstanding Promise Award, Research Excellence Award (American Journal of Physiology), and Ludwig Institute for Cancer Research Excellence Medal.

Research overview

The Molecular Proteomics laboratory is focused on understanding the molecular function of nano-sized extracellular vesicles and how their intercellular signalling is important in normal physiology and pathologies; including cancer and cardiometabolic disease with the goal of identifying new deliverable therapeutic targets.

We use a multi-disciplinary approach to understand the molecular function of extracellular vesicles incorporating proteomics, cell biology, molecular biology, nanobiotechnology, functional assays, cell and animal models, with the goal of understanding mechanisms of cell signalling and function, identifying deliverable therapeutic targets and engineering nanoparticles for next generation cell-free therapies.

  • Understanding targeted delivery of biological and engineered extracellular vesicles.
  • Barcoding circulating extracellular vesicles – understanding organ-specific intercellular signalling.
  • Repairing a broken heart: exosomes and nanocarriers in cardiac repair.
  • Demystifying what makes up a heart using ultra-sensitive proteomics.
  • Mechanisms of cellular reprogramming by extracellular vesicles.
  • Investigating quantitative labelling strategies (chemical peptide tags and metabolic labelling) for multiplexed quantitative proteomics.

Achievements

  • Helen Amelia Hains Fellow
  • President, Australia and New Zealand Society of Extracellular Vesicles
  • Ludwig Institute for Cancer Research Excellence Medal
  • International Protein Society Hans Neurath Outstanding Promise Award
  • ROYAN International Research Award on Reproductive Biomedicine
  • Inaugural LIMS Stone Protein Chemistry Fellowship

Support us

With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.

Find out more